Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

45.000
+1.2402.83%
Volume:3.12M
Turnover:139.22M
Market Cap:298.67B
PE:32.62
High:45.400
Open:43.700
Low:43.020
Close:43.760
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.05
T/O Rate:1.21%
Dividend:0.23
Dividend Rate:0.52%
EPS(LYR):1.380
ROE:12.46%
ROA:7.02%
PB:3.96
PE(LYR):32.62
PS:8.16

Loading ...

Movement Alert|HENGRUI PHARMA Falls 3.09% in Regular Trading, Trading at HK$56.35

Market Focus
·
Aug 06

Cross-Market Valuation Disparities: Top A-H Share Premium Rankings as of August 5th

Stock News
·
Aug 05

Hengrui Pharmaceuticals Gets China Nod for Lung Cancer Combo Trials

MT Newswires Live
·
Aug 05

Hengrui Pharma Completes 13.75 Million Share Buyback as of July 31

Stock News
·
Aug 04

HENGRUI PHARMA's Subsidiary Secures Approval for Clinical Trial Initiation

Stock News
·
Aug 04

Hengrui Pharma Maintains Stable H-Share Base; Repurchases 0.28 Million A-Shares in July

Bulletin Express
·
Aug 04

Dual-Listed Stock Premium Snapshot: August 3 Market Close

Stock News
·
Aug 03

Metis TechBio Jumps on Jiangsu Hengrui-tie up on AI Formulation Platform

Reuters
·
Aug 03

METIS TECHBIO-P Deploys AI Drug Formulation Platform at HENGRUI PHARMA, Accelerating NanoForge Commercialization

Stock News
·
Aug 03

The Capital Group Companies Increases Stake in Hengrui Pharma with 483,600 Share Purchase at Approximately HK$57.90 Each

Deep News
·
Aug 03

AH Share Premium Rankings for July 31

Stock News
·
Jul 31

AH Share Premium Ranking Update: July 30 Market Close

Stock News
·
Jul 30

Movement Alert|HENGRUI PHARMA Falls 3.17% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure Despite Multiple Positive Catalysts

Market Focus
·
Jul 30

Hengrui Pharma Wins China Regulator's Nod for Three Drugs

MT Newswires Live
·
Jul 30

Capital Group Boosts Stake in Hengrui Pharma with 752,200 Share Purchase

Deep News
·
Jul 30

Hengrui Pharma Secures NMPA Nod for China’s First Home-grown Long-Acting Insulin Analog

Bulletin Express
·
Jul 29

Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval

Stock News
·
Jul 29

Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog

Stock News
·
Jul 29

Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads

Stock News
·
Jul 29

Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission

Stock News
·
Jul 29